Pepex Biomedical is a medical device contract development and manufacturing organization (CDMO) that has developed a breakthrough generation of biosensors that have the potential to make a significantly positive impact on diagnostic medical testing. Our advanced sensor designs are capable of measuring metabolic analytes at the cellular level which equates to improved patient outcomes.

With our extensive Intellectual Property (IP) portfolio of +300 global patents that protect our proprietary manufacturing processes and biosensor designs, we are  capable of identifying hundreds of unique biomarkers which indicate the presence, and in certain situations the concentration level of, cancers, lactic acid, sepsis, Alzheimer’s, HIV, Ebola, hepatitis, Traumatic Brain Injury (TBI), tuberculosis, CV-19, and other life-altering conditions quickly, easily, and cost effectively in saliva, blood, and interstitial fluid.

Our proprietary biosensor technologies are referred to individually as Composite Conductive Monofilament (CCM^®), 3 Electrode (3E™), and Lansing Sensor (LS^®), and are identified collectively as Pepex Biosensor Technology (PBT). These PBT applications involve integrating from 1 to many polyetheretherketone (PEEK) fibers, each roughly the size of a human hair, inside a physical space as small as a 32-guage cannula. Using the Company’s patented three-dimensional, nanoparticle Aerosol Jet Printing (AJP) techniques, analyte-specific chemistry is applied to PEEK fibers which may be inserted into a range of various sizes and form factors for specific use cases.

Recently, the Company has also developed its AnalyteAI™ artificial intelligence competency which may be applied to provide near real-time data analysis of diagnostic samples.